Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul-Dec;14(2):103-116.
doi: 10.4103/ajts.ajts_192_20. Epub 2020 Dec 19.

Haemovigilance Programme of India: Comparative analysis of transfusion reactions reported over a 5-year period through two reporting formats and key recommendations for blood safety

Akanksha Bisht  1 , Neelam Marwaha  2 , Ravneet Kaur  3 , Debasish Gupta  4 , Reba Chhabra  1
Affiliations

Haemovigilance Programme of India: Comparative analysis of transfusion reactions reported over a 5-year period through two reporting formats and key recommendations for blood safety

Akanksha Bisht et al. Asian J Transfus Sci. 2020 Jul-Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Year-wise new Centres Enrolled under HvPI. 126* centers were enrolled in 2016 from January 1 to April 30 and were included in 2013–2016 report published in 2018 before the new version of Haemo-Vigil software was launched on May 1, 2016
Figure 2
Figure 2
Month-wise active centers in 2016
Figure 3
Figure 3
Month-wise active centers in 2017
Figure 4
Figure 4
Year-wise number of reports submitted to Haemovigilance Programme of India. *338 reports of 2016 reported via transfusion reaction reporting form 1.0 from January 1, 2016, to April 30, 2016, were analyzed and published in 2013–2016 report
Figure 5
Figure 5
Distribution of reactions and reports from 2013 to 2017
Figure 6
Figure 6
Mortality, transfusion reaction, and Imputability. IHA = Immunological Hemolysis due to other AlloAntibodies; FNHTR = Febrile Nonhemolytic Transfusion Reactions; HyTR = Hypotensive Transfusion Reaction; IHABO = Immunological Hemolysis due to ABO Incompatibility; NIH = Nonimmunological Hemolysis; TACO = Transfusion-Associated Circulatory Overload; TAD = Transfusion-Associated Dyspnea; TRALI = Transfusion-Related Acute Lung Injury; TTBI = Transfusion-Transmitted Bacterial Infection; TAH = Transfusion-associated hypertension. a and b denotes two reactions in one report respectively
Figure 7
Figure 7
Incidence of adverse transfusion reactions per 10,000 of blood products transfused in 2016–2017
Figure 8
Figure 8
Details of blood products transfused (2016–2017)
Figure 9
Figure 9
Implication rate in 2016 and 2017
Figure 10
Figure 10
Overall distribution of reactions reported to Haemovigilance Programme of India from 2013 to 2017
Figure 11
Figure 11
Outcome of adverse transfusion reactions year wise
Figure 12
Figure 12
Time gap of blood products
Figure 13
Figure 13
Febrile nonhemolytic transfusion reactions cases reported
Figure 14
Figure 14
Year-wise implication rate of blood products
Figure 15
Figure 15
Transfusion frequency wise distribution of febrile nonhemolytic transfusion reactions
Figure 16
Figure 16
Distribution of outcome of febrile nonhemolytic transfusion reactions for the years 2013–2017
Figure 17
Figure 17
Allergic reaction cases reported
Figure 18
Figure 18
Year-wise implication rate of blood products
Figure 19
Figure 19
Anaphylaxis cases reported
Figure 20
Figure 20
Transfusion frequency wise distribution of anaphylaxis
Figure 21
Figure 21
Implication rate of blood products
Figure 22
Figure 22
Hypotensive transfusion reaction cases reported
Figure 23
Figure 23
Transfusion frequency-wise distribution
Figure 24
Figure 24
Immunological hemolysis due to ABO Incompatibility cases reported
Figure 25
Figure 25
Immunological hemolysis due to ABO incompatibility cases reported
Figure 26
Figure 26
Cause of ABO incompatibility reported
Figure 27
Figure 27
Immunological hemolysis due to ABO Incompatibility cases reported
Figure 28
Figure 28
Implicated blood products
Figure 29
Figure 29
Transfusion-associated circulatory overload cases reported
Figure 30
Figure 30
Transfusion-associated dyspnea cases reported
Figure 31
Figure 31
Transfusion-related acute lung injury cases reported
Figure 32
Figure 32
Implicated blood products
Figure 33
Figure 33
Transfusion-transmitted bacterial infection cases reported
Figure 34
Figure 34
Year-wise distribution of other reactions
See this image and copyright information in PMC

References

    1. Bisht A, Marwaha N, Kaur R, Gupta D, Singh S. Haemovigilance Programme of India: Analysis of transfusion reactions reported from January 2013 to April 2016 and key recommendations for blood safety. Asian J Transfus Sci. 2018;12:1–7. - PMC - PubMed
    1. Marwaha N, Singh S, Bisht A. Setting up haemovigilance from the very first step.The Indian perspective. Voxs. 2014;9:178–83.
    1. Mukherjee S, Maiti R. Haemovigilance: A current update in Indian perspective. JCDR. 2016;10:EE05–9. - PMC - PubMed
    1. Shivgunde P, Besekar S, Bhojwani K, Bhojwani D. Knowledge, attitude and practice of haemovigilance amongst healthcare professionals in Nashik, Maharashtra, India. IJBCP. 2018;7:986–91.
    1. International Society of Blood Transfusiion Working Party on Haemovigilance. Proposed Standard Definitions for Surveillance of Non-Infectious Adverse Transfusion Reactions. 2011. [Last accessed on 2020 Oct 16]. Available from: http//www.isbtweb.org/Haemovigilance/ISBT_definitions_final_2011 .